For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase ( ...

A study reveals that a personalized approach, considering age, sex and size, improves the diagnosis of hypertrophic ...

Tenaya plans to present data from its pediatric non-interventional natural history study, known as MyClimb, in the second ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...

Trametinib is a mitogen-activated protein kinase (MEK) inhibitor and the research findings are published in JACC: Basic to Translational Science highlights the urgent medical assistance for ...

Tenaya Therapeutics (TNYA) provided an update on its clinical development programs and outlined its strategic priorities for 2025. Updates: ...

An initiative to improve care and standardize identification, assessment, referrals, and treatment for patients with HCM has been launched by the AHA.

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS ...

WOMEN are missing out on diagnosis of a potentially deadly heart condition which affects one in 500 people, says new research ...